全文获取类型
收费全文 | 1814篇 |
免费 | 114篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 49篇 |
儿科学 | 99篇 |
妇产科学 | 17篇 |
基础医学 | 328篇 |
口腔科学 | 46篇 |
临床医学 | 169篇 |
内科学 | 311篇 |
皮肤病学 | 28篇 |
神经病学 | 122篇 |
特种医学 | 106篇 |
外国民族医学 | 2篇 |
外科学 | 219篇 |
综合类 | 22篇 |
预防医学 | 127篇 |
眼科学 | 16篇 |
药学 | 168篇 |
中国医学 | 1篇 |
肿瘤学 | 101篇 |
出版年
2023年 | 8篇 |
2020年 | 16篇 |
2019年 | 18篇 |
2018年 | 24篇 |
2017年 | 28篇 |
2016年 | 24篇 |
2015年 | 40篇 |
2014年 | 42篇 |
2013年 | 59篇 |
2012年 | 76篇 |
2011年 | 71篇 |
2010年 | 75篇 |
2009年 | 55篇 |
2008年 | 64篇 |
2007年 | 65篇 |
2006年 | 66篇 |
2005年 | 54篇 |
2004年 | 64篇 |
2003年 | 53篇 |
2002年 | 65篇 |
2001年 | 51篇 |
2000年 | 29篇 |
1999年 | 41篇 |
1998年 | 35篇 |
1997年 | 40篇 |
1996年 | 36篇 |
1995年 | 39篇 |
1994年 | 31篇 |
1993年 | 43篇 |
1992年 | 34篇 |
1991年 | 28篇 |
1990年 | 38篇 |
1989年 | 37篇 |
1988年 | 46篇 |
1987年 | 37篇 |
1986年 | 37篇 |
1985年 | 31篇 |
1984年 | 16篇 |
1983年 | 18篇 |
1982年 | 10篇 |
1981年 | 19篇 |
1979年 | 12篇 |
1978年 | 15篇 |
1976年 | 15篇 |
1975年 | 8篇 |
1974年 | 10篇 |
1970年 | 10篇 |
1876年 | 8篇 |
1872年 | 9篇 |
1868年 | 8篇 |
排序方式: 共有1931条查询结果,搜索用时 15 毫秒
1.
D Gröne† R Treudler† EM de Villiers‡ R Husak† CE Orfanos† ChC Zouboulis†§ 《Journal of the European Academy of Dermatology and Venereology》2006,20(2):202-205
Cidofovir is an acyclic nucleoside phosphonate with broad-spectrum activity against DNA viruses, including human papilloma virus (HPV). However, data on the efficacy of cidofovir in an immunosuppressive setting remain contradictory. We report for the first time on the promotion of the healing of recalcitrant warts in a patient with myelodysplastic syndrome with intravenous cidofovir treatment. 相似文献
2.
3.
Dr. B. H.Ch. Stricker R. R. M. de Groot J. H. P. Wilson 《European journal of clinical pharmacology》1991,40(4):367-371
Summary In 1981 generalized anaphylaxis was registered on 166 occasions in Dutch general and academic hospitals. Clinical details of 120 of those patients revealed that in 107 anaphylaxis was either probable (n=90) or possible (n=17), whereas in 13 cases some other reaction than anaphylaxis had occurred. The series of confirmed cases contained 46 men and 61 women, with mean ages of 47 y and 48 y, respectively.There was a complete recovery in 102 patients and two patients died. Hypotension was present in 79 cases (74%), dyspnoea in 34 cases (32%) and a skin reaction, mainly urticaria, erythema or angioedema, was mentioned in 62 cases (58%). Most cases of anaphylaxis were drug-induced (76%), the main causes being the analgesic glafenine and contrast media. Glafenine was mentioned as the cause in 36% of all admissions for drug-induced anaphylaxis. Only 3.7% of cases had been reported to the voluntary reporting scheme of the Netherlands Centre for Monitoring of Adverse Reactions to Drugs.On the basis of reimbursement data, the risk of developing severe anaphylaxis to glafenine was estimated at 11.7–19.3-fold relative to indomethacin, and 13.4–20.2-fold relative to oral penicillins. 相似文献
4.
5.
J. P. Ottervanger B. H. C. Stricker T. B. van Witsen H. A. Valkenburg D. E. Grobbee 《European journal of clinical pharmacology》1994,47(4):305-309
There are several reports on cardiac adverse reactions attributed to the antimigraine drug sumatriptan in the recent literature. In order to assess the frequency and the character of adverse reactions to sumatriptan, a postmarketing cohort study was performed one year after registration of the drug in The Netherlands. With assistance of 86% of the drug dispensing general practitioners in The Netherlands, 1727 patients who had received sumatriptan were traced in July, 1992. Via their general practitioners, a questionnaire about use of sumatriptan, adverse reactions and other medication was sent to the patients in December 1992. During the study period, seven patients were lost to follow-up. Of the 1720 remaining patients, 1202 (70%) responded to the questionnaire, of whom 1187 had actually used sumatriptan. The most frequently reported suspected adverse reactions were paraesthesiae (139 patients, 95% CI 9.9%–13.5%) and dizziness (96 patients, 95% CI 6.5%–9.7%). Chest pain after use of sumatriptan was reported by 94 patients (7.9%, 95% CI 6.4%–9.4%), and according to the close temporal relationship with the intake of sumatriptan and a positive rechallenge, a causal relationship was probable in most of those patients. The frequency of chest pain attributed to sumatriptan was higher in females (9.0% vs 4.6%; relative risk 1.9, 95% CI 1.1–3.4). Age and hypertension were not associated with chest pain attributed to sumatriptan. Dyspnoea attributed to sumatriptan was reported by 26 patients (2.2%), and was associated with obstructive lung disease (relative risk 5.4 95% CI 1.7–16.9). Thus, in view of the high frequency of chest pain after use of sumatriptan and reports in the literature of cardiac disturbances, including myocardial infarction, cautious use of the drug is advised. 相似文献
6.
7.
Gysèle S Bleumink Anna F C Schut Miriam C J M Sturkenboom Jaap W Deckers Cornelia M van Duijn Bruno H Ch Stricker 《Genetics in medicine》2004,6(6):465-474
Heart failure is a complex clinical syndrome. There is evidence for a genetic contribution to the pathophysiology of heart failure. Considering the fundamental role of neurohormonal factors in the pathophysiology and progression of cardiac dysfunction and hypertrophy, variants of genes involved in this system are logical candidate genes in heart failure. In this report, genetic polymorphisms of the major neurohormonal systems in heart failure will be discussed. Studies on polymorphisms of the renin-angiotensin-aldosterone system (RAAS), adrenergic receptor polymorphisms, endothelin (receptor) polymorphisms, and a group of miscellaneous polymorphisms that may be involved in the development or phenotypic expression of heart failure will be reviewed. Research on left ventricular hypertrophy is also included. The majority of genetic association studies focused on the ACE I/D polymorphism. Initial genetic associations have often been difficult to replicate, mainly due to problems in study design and lack of power. Promising results have been obtained with genetic polymorphisms of the RAAS and sympathetic system. Considering the evidence so far, a modifying role for these polymorphisms seems more likely than a role of these variants as susceptibility genes. Besides the need for larger studies to examine the effects of single nucleotide polymorphisms and haplotypes, future studies also need to focus on the complexity of these systems and study gene-gene interactions and gene-environment interactions. 相似文献
8.
The receptor tyrosine kinase (RTK) Ret is activated by the formation of a complex consisting of ligands such as glial cell line-derived neurotrophic factor (GDNF) and glycerophosphatidylinositol-anchored coreceptors termed GFRalphas. During activation, Ret translocates into lipid rafts, which is critical for functional responses to GDNF. We found that Ret was rapidly ubiquitinated and degraded in sympathetic neurons when activated with GDNF, but, unlike other RTKs that are trafficked to lysosomes for degradation, Ret was degraded predominantly by the proteasome. After GDNF stimulation, the majority of ubiquitinated Ret was located outside of lipid rafts and Ret was lost predominantly from nonraft membrane domains. Consistent with the predominance of Ret degradation outside of rafts, disruption of lipid rafts in neurons did not alter either the GDNF-dependent ubiquitination or degradation of Ret. GDNF-mediated survival of sympathetic neurons was inhibited by lipid raft depletion, and this inhibitory effect of raft disruption on GDNF-mediated survival was reversed if Ret degradation was blocked via proteasome inhibition. Therefore, lipid rafts sequester Ret away from the degradation machinery located in nonraft membrane domains, such as Cbl family E3 ligases, thereby sustaining Ret signaling. 相似文献
9.
R Rupprecht A Lippold C Auras G Bramkamp C Breitkopf H-J Elsmann EM Habenicht V Jasnoch H Müller-Pannes K-W Schulte L Suter 《Journal of the European Academy of Dermatology and Venereology》2007,21(2):178-185
Background Cosmetic changes are to be expected after radiotherapy for skin tumours. Objectives This study aimed to answer the questions: How frequent are cosmetic changes after soft X‐ray therapy? Do treatment parameters, tumour thickness, localization and size of the irradiated field have a major influence? Were patients irritated by the visual appearance of the irradiated field? Methods In total, 2474 examinations of 1149 irradiated fields were performed. Results Hypopigmentation was found in 64.7% of examinations more than 90 days after therapy, teleangiectases in 43.1%, erythema in 24.8%, and hyperpigmentation in 16.8%. The frequency of hypopigmentation, teleangiectases and hyperpigmentation increased with time from X‐ray exposure; more than 4 years after therapy hypopigmentation was diagnosed in 91.8% and teleangiectases in 82.2% of examinations. Total dose, the time–dose–fractionation factor (TDF), field size and dose per fraction were significantly related to the frequency of cosmetic changes. Incidence rates of cosmetic changes differed by less than 15% if different treatment conditions were compared: thicker vs. thinner tumours, larger vs. smaller fields, higher vs. lower total doses, doses per fraction, and TDF. Frequencies of hypopigmentation, teleangiectases, erythema and hyperpigmentation differed by more than 15% between some localizations on the head. Women reported irritation by the visual appearance of the irradiated field in 12.6% of 1116 interviews, and men in 4.4% of 1284 interviews. Conclusions Cosmetic changes after soft X‐ray therapy are relatively frequent. Treatment parameters, tumour thickness and field size have only a minor influence. Few patients, but more women than men, were irritated by the visual appearance of the irradiated field. 相似文献
10.